AU2008250945B2 - Bone targeted alkaline phosphatase, kits and methods of use thereof - Google Patents

Bone targeted alkaline phosphatase, kits and methods of use thereof Download PDF

Info

Publication number
AU2008250945B2
AU2008250945B2 AU2008250945A AU2008250945A AU2008250945B2 AU 2008250945 B2 AU2008250945 B2 AU 2008250945B2 AU 2008250945 A AU2008250945 A AU 2008250945A AU 2008250945 A AU2008250945 A AU 2008250945A AU 2008250945 B2 AU2008250945 B2 AU 2008250945B2
Authority
AU
Australia
Prior art keywords
alkaline phosphatase
amino acid
sequence
residue
signal peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2008250945A
Other languages
English (en)
Other versions
AU2008250945A2 (en
AU2008250945A1 (en
Inventor
Guy Boileau
Philippe Crine
Robert Heft
Hal Landy
Isabelle Lemire
Pierre Leonard
Thomas P. Loisel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2008250945A1 publication Critical patent/AU2008250945A1/en
Publication of AU2008250945A2 publication Critical patent/AU2008250945A2/en
Assigned to ENOBIA CANADA LIMITED PARTNERSHIP reassignment ENOBIA CANADA LIMITED PARTNERSHIP Request for Assignment Assignors: ENOBIA PHARMA INC.
Assigned to ALEXION PHARMA INTERNATIONAL SARL reassignment ALEXION PHARMA INTERNATIONAL SARL Request for Assignment Assignors: ENOBIA CANADA LIMITED PARTNERSHIP
Priority to AU2013203875A priority Critical patent/AU2013203875A1/en
Assigned to ALEXION PHARMA HOLDING reassignment ALEXION PHARMA HOLDING Request for Assignment Assignors: ALEXION PHARMA INTERNATIONAL SARL
Application granted granted Critical
Publication of AU2008250945B2 publication Critical patent/AU2008250945B2/en
Assigned to ALEXION PHARMACEUTICALS, INC. reassignment ALEXION PHARMACEUTICALS, INC. Request for Assignment Assignors: ALEXION PHARMA HOLDING
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AU2008250945A 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof Active 2031-01-14 AU2008250945B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013203875A AU2013203875A1 (en) 2007-05-11 2013-04-11 Bone Targeted Alkaline Phosphatase, Kits and Methods of Use Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
US60/917,589 2007-05-11
PCT/CA2008/000923 WO2008138131A1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013203875A Division AU2013203875A1 (en) 2007-05-11 2013-04-11 Bone Targeted Alkaline Phosphatase, Kits and Methods of Use Thereof

Publications (3)

Publication Number Publication Date
AU2008250945A1 AU2008250945A1 (en) 2008-11-20
AU2008250945A2 AU2008250945A2 (en) 2009-12-24
AU2008250945B2 true AU2008250945B2 (en) 2013-12-12

Family

ID=40001639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008250945A Active 2031-01-14 AU2008250945B2 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Country Status (25)

Country Link
US (1) US20100297119A1 (OSRAM)
EP (3) EP2158319B1 (OSRAM)
JP (1) JP5732603B2 (OSRAM)
AT (1) ATE536413T1 (OSRAM)
AU (1) AU2008250945B2 (OSRAM)
BR (2) BR122019000505B1 (OSRAM)
CA (1) CA2687001C (OSRAM)
CY (1) CY2016005I2 (OSRAM)
DE (1) DE202008018131U1 (OSRAM)
DK (3) DK2158319T3 (OSRAM)
ES (3) ES2380546T3 (OSRAM)
FR (1) FR16C0007I2 (OSRAM)
HR (1) HRP20140416T1 (OSRAM)
HU (2) HUE031655T2 (OSRAM)
IL (1) IL202057A0 (OSRAM)
LT (1) LTC2368999I2 (OSRAM)
LU (1) LU92976I2 (OSRAM)
ME (1) ME01828B (OSRAM)
NL (1) NL300798I1 (OSRAM)
NO (1) NO2016002I1 (OSRAM)
PL (3) PL2662448T3 (OSRAM)
PT (3) PT2662448T (OSRAM)
RS (1) RS53302B (OSRAM)
SI (2) SI2662448T1 (OSRAM)
WO (1) WO2008138131A1 (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
WO2008151088A2 (en) 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
BR112012027765A2 (pt) * 2010-04-30 2019-09-24 Enobia Pharma Inc métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
EP2598533B1 (en) 2010-07-28 2019-02-20 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
WO2013058833A1 (en) * 2011-10-19 2013-04-25 Enobia Canada Limited Partnership Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
CN106164262B (zh) * 2014-01-24 2020-08-07 安-法玛公司 嵌合型碱性磷酸酶样蛋白
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX389350B (es) * 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AU2016297862C1 (en) 2015-07-24 2022-12-15 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding
KR102644116B1 (ko) * 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 알칼린 포스파타제의 제조
WO2017058822A1 (en) * 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) * 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CA3019726A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. EFFECTS OF METALS ON THE PRODUCTION OF ALKALINE PHOSPHATASES
US11034775B2 (en) 2016-06-07 2021-06-15 Gliknik Inc. Cysteine-optimized stradomers
ES2887573T3 (es) 2016-06-27 2021-12-23 Alexion Pharma Inc Métodos para el tratamiento de la hipofosfatasia en niños y adolescentes
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
AU2017367699B2 (en) * 2016-11-30 2023-12-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
KR20190093186A (ko) 2016-12-09 2019-08-08 글리크닉 인코포레이티드 다가 Fc 화합물에 의해 염증성 장애를 치료하는 방법
PE20191354A1 (es) 2016-12-09 2019-10-01 Gliknik Inc Optimizacion de fabricacion de gl-2045, un stradomer multimerizante
JP7142021B2 (ja) * 2017-03-09 2022-09-26 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質製造プロセス
JP2020512363A (ja) * 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 成人及び青年における低ホスファターゼ症（ｈｐｐ）を治療する方法
WO2019067502A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
KR20220005560A (ko) 2019-05-06 2022-01-13 신세틱 바이오로직스, 인코퍼레이티드 알칼리성 포스페이트-기반 종양학 치료제
JP2023504208A (ja) * 2019-12-09 2023-02-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
US12478662B2 (en) 2020-01-03 2025-11-25 The United States of America as represented by the Secretary Department of Heath and Human Services TNAP locally administered for promoting periodontal health
CA3190513A1 (en) * 2020-09-03 2022-03-10 Jeffrey S. Bartlett Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
US12083169B2 (en) * 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CA3263089A1 (en) * 2022-08-31 2024-03-07 University Of Utah Research Foundation GJA1-20K COMPOSITIONS AND METHODS FOR MITIGATING ISCHEMIC-REPERFUSION INJURY

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103263A1 (en) * 2004-04-21 2005-11-03 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
WO2001036620A2 (en) 1999-11-16 2001-05-25 Genzyme Corporation Vectors and transgenies with regulatory elements for gene delivery to the liver
DE60233047D1 (de) 2001-05-14 2009-09-03 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
MXPA06014972A (es) 2004-06-23 2007-03-07 Genzyme Corp Metodos y composiciones para el tratamiento de enfermedades poliquisticas.
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
JP2008521575A (ja) 2004-12-01 2008-06-26 ジェンザイム・コーポレイション 肝臓を標的とした遺伝物質の送達方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103263A1 (en) * 2004-04-21 2005-11-03 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone

Also Published As

Publication number Publication date
BRPI0811198A2 (pt) 2014-10-21
PT2368999E (pt) 2014-05-26
PT2662448T (pt) 2017-03-29
AU2008250945A2 (en) 2009-12-24
RS53302B (sr) 2014-08-29
DK2158319T3 (da) 2012-03-19
HK1141047A1 (en) 2010-10-29
HK1191372A1 (en) 2014-07-25
WO2008138131A4 (en) 2008-12-31
HK1162589A1 (en) 2012-08-31
LU92976I2 (en) 2016-04-11
WO2008138131A1 (en) 2008-11-20
CY2016005I1 (el) 2016-08-31
BR122019000505A2 (pt) 2021-12-14
BRPI0811198A8 (pt) 2018-08-14
HRP20140416T1 (hr) 2014-06-20
EP2158319B1 (en) 2011-12-07
IL202057A0 (en) 2011-08-01
AU2008250945A1 (en) 2008-11-20
EP2158319A1 (en) 2010-03-03
PL2368999T3 (pl) 2014-08-29
NO2016002I2 (no) 2016-02-02
ATE536413T1 (de) 2011-12-15
SI2662448T1 (sl) 2017-05-31
BR122019000505B1 (pt) 2022-01-18
BRPI0811198B8 (pt) 2021-05-25
LTC2368999I2 (lt) 2017-09-25
ES2471915T3 (es) 2014-06-27
BRPI0811198B1 (pt) 2021-03-09
SI2368999T1 (sl) 2014-07-31
JP2010526543A (ja) 2010-08-05
EP2662448B1 (en) 2016-12-21
EP2368999A1 (en) 2011-09-28
FR16C0007I1 (OSRAM) 2016-04-15
NL300798I2 (OSRAM) 2016-03-16
US20100297119A1 (en) 2010-11-25
CA2687001C (en) 2019-02-12
EP2158319A4 (en) 2010-07-21
PL2158319T3 (pl) 2012-05-31
PL2662448T3 (pl) 2017-07-31
CA2687001A1 (en) 2008-11-20
ES2380546T3 (es) 2012-05-16
ME01828B (me) 2014-12-20
PT2158319E (pt) 2012-03-06
DK2662448T3 (en) 2017-03-20
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
WO2008138131A9 (en) 2009-08-06
EP2368999B1 (en) 2014-03-12
ES2619332T3 (es) 2017-06-26
PL2158319T4 (pl) 2016-04-29
NO2016002I1 (no) 2016-02-02
HUS1600005I1 (hu) 2016-02-29
DK2368999T3 (da) 2014-05-26
NL300798I1 (OSRAM) 2016-03-16
CY2016005I2 (el) 2016-08-31
FR16C0007I2 (fr) 2017-01-27
DE202008018131U1 (de) 2011-12-30
JP5732603B2 (ja) 2015-06-10
LTPA2016004I1 (lt) 2016-02-25

Similar Documents

Publication Publication Date Title
AU2008250945B2 (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
US11224638B2 (en) Treating seizure with recombinant alkaline phosphatase
US9988620B2 (en) Methods, compositions, and kits for the treatment of matrix mineralization disorders
HK1191372B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1162589B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1141047B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
AU2013203875A1 (en) Bone Targeted Alkaline Phosphatase, Kits and Methods of Use Thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 NOV 2009

PC1 Assignment before grant (sect. 113)

Owner name: ENOBIA CANADA LIMITED PARTNERSHIP

Free format text: FORMER APPLICANT(S): ENOBIA PHARMA INC.

PC1 Assignment before grant (sect. 113)

Owner name: ALEXION PHARMA INTERNATIONAL SARL

Free format text: FORMER APPLICANT(S): ENOBIA CANADA LIMITED PARTNERSHIP

PC1 Assignment before grant (sect. 113)

Owner name: ALEXION PHARMA HOLDING

Free format text: FORMER APPLICANT(S): ALEXION PHARMA INTERNATIONAL SARL

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALEXION PHARMACEUTICALS, INC.

Free format text: FORMER OWNER WAS: ALEXION PHARMA HOLDING

NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: STRENSIQ ASFOTASE ALFA RCH

Filing date: 20160114

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: STRENSIQ ASFOTASE ALFA RCH

Filing date: 20160114

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: STRENSIQ ASFOTASE ALFA RCH

Filing date: 20160114

Extension date: 20310114